T. Jake Liang，NIH，马里兰——HBV相关实验室及人物介绍系列

bigben446

T. Jake Liang，NIH，马里兰——HBV相关实验室及人物介绍系列

T. Jake Liang，NIH，马里兰
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

Thomas, E. and T. J. Liang (2016). "Experimental models of hepatitis B and C - new insights and progress." Nat Rev Gastroenterol Hepatol.
Liang, T. J. (2016). "Virology: The X-Files of hepatitis B." Nature 531(7594): 313-4.
Gara, N. and A. Abdalla, et al. (2015). "Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults." Clin Infect Dis 60(4): 505-13.
Pene, V. and Q. Li, et al. (2015). "Dynamic Interaction of Stress Granules, DDX3X, and IKK-alpha Mediates Multiple Functions in Hepatitis C Virus Infection." J Virol 89(10): 5462-77.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Liang, T. J. and M. G. Ghany (2014). "Therapy of hepatitis C--back to the future." N Engl J Med 370(21): 2043-7.
Heller, T. and Y. Rotman, et al. (2014). "Long-term therapy of chronic delta hepatitis with peginterferon alfa." Aliment Pharmacol Ther 40(1): 93-104.
Sugiyama, N. and A. Murayama, et al. (2014). "Single strain isolation method for cell culture-adapted hepatitis C virus by end-point dilution and infection." PLoS One 9(5): e98168.
Guedj, J. and Y. Rotman, et al. (2014). "Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling." Hepatology 60(6): 1902-10.
Lucifora, J. and Y. Xia, et al. (2014). "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA." Science 343(6176): 1221-8.
Liang, T. J. (2013). "Current progress in development of hepatitis C virus vaccines." Nat Med 19(7): 869-78.
Han, H. and M. Noureddin, et al. (2013). "Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype." J Hepatol 59(5): 957-63.
Ghany, M. G. and T. J. Liang (2013). "Current and future therapies for hepatitis C virus infection." N Engl J Med 369(7): 679-80.
Edlich, B. and G. Ahlenstiel, et al. (2012). "Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients." Hepatology 55(1): 39-48.
Kandiah, E. and N. R. Watts, et al. (2012). "Cryo-EM study of Hepatitis B virus core antigen capsids decorated with antibodies from a human patient." J Struct Biol 177(1): 145-51.
Ghany, M. G. and J. J. Feld, et al. (2012). "Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B." Aliment Pharmacol Ther 35(9): 1027-35.
Zeissig, S. and K. Murata, et al. (2012). "Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity." Nat Med 18(7): 1060-8.
Lok, A. S. and J. W. Ward, et al. (2012). "Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable." Ann Intern Med 156(10): 743-5.
Alter, H. J. and T. J. Liang (2012). "Hepatitis C: the end of the beginning and possibly the beginning of the end." Ann Intern Med 156(4): 317-8.
Feld, J. J. and A. A. Modi, et al. (2011). "S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders." Gastroenterology 140(3): 830-9.
Veerapu, N. S. and S. Raghuraman, et al. (2011). "Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses." Gastroenterology 140(2): 676-685.e1.
Ahlenstiel, G. and B. Edlich, et al. (2011). "Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C." Gastroenterology 141(4): 1231-9, 1239.e1-2.
Zhang, Z. and E. Sun, et al. (2010). "Inhibition of cellular proteasome activities mediates HBX-independent hepatitis B virus replication in vivo." J Virol 84(18): 9326-31.
Liang, T. J. and K. T. Mok, et al. (2010). "Hepatitis B genotype C correlated with poor surgical outcomes for hepatocellular  carcinoma." J Am Coll Surg 211(5): 580-6.
de Mochel, N. S. and S. Seronello, et al. (2010). "Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection." Hepatology 52(1): 47-59.
Li, Q. and A. L. Brass, et al. (2009). "A genome-wide genetic screen for host factors required for hepatitis C virus propagation." Proc Natl Acad Sci U S A 106(38): 16410-5.
Liang, T. J. (2009). "Hepatitis B: the virus and disease." Hepatology 49(5 Suppl): S13-21.
Palmore, T. N. and N. L. Shah, et al. (2009). "Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression." Clin Gastroenterol Hepatol 7(10): 1130-7.
Loomba, R. and A. K. Rowley, et al. (2008). "Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis." Clin Gastroenterol Hepatol 6(6): 696-700.
Loomba, R. and A. Rowley, et al. (2008). "Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy." Ann Intern Med 148(7): 519-28.
Pawlotsky, J. M. and G. Dusheiko, et al. (2008). "Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach." Gastroenterology 134(2): 405-15.
Su, X. and L. J. Yee, et al. (2008). "Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C." J Hepatol 49(2): 184-91.
Rhodes, S. L. and H. Erlich, et al. (2008). "Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection." Genes Immun 9(4): 328-33.
Ghany, M. and T. J. Liang (2007). "Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B." Gastroenterology 132(4): 1574-85.
Kato, T. and T. Matsumura, et al. (2007). "Production of infectious hepatitis C virus of various genotypes in cell cultures." J Virol 81(9): 4405-11.
Hoofnagle, J. H. and E. Doo, et al. (2007). "Management of hepatitis B: summary of a clinical research workshop." Hepatology 45(4): 1056-75.
Huang, Y. and J. J. Feld, et al. (2007). "Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C." Gastroenterology 132(2): 733-44.
Huang, Y. and H. Yang, et al. (2007). "A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection." Proc Natl Acad Sci U S A 104(3): 985-90.
Loomba, R. and T. J. Liang (2007). "Treatment of chronic hepatitis B." Antivir Ther 12 Suppl 3: H33-41.
Liang, T. J. (2007). "Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?" N Engl J Med 357(2): 176-8.
Yu, X. and M. Qiao, et al. (2007). "Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles." Virology 367(1): 126-34.
Yee, L. J. and Y. M. Tang, et al. (2007). "Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus." Hepatology 46(1): 74-83.
Perumalswami, P. and D. E. Kleiner, et al. (2006). "Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection." Hepatology 43(4): 780-7.
Hu, Z. and Z. Zhang, et al. (2006). "Altered proteolysis and global gene expression in hepatitis B virus X transgenic  mouse liver." J Virol 80(3): 1405-13.
Loomba, R. and T. J. Liang (2006). "Novel approaches to new therapies for hepatitis B virus infection." Antivir Ther 11(1): 1-15.
Feld, J. J. and T. J. Liang (2006). "Hepatitis C -- identifying patients with progressive liver injury." Hepatology 43(2 Suppl 1): S194-206.
Barth, H. and T. J. Liang, et al. (2006). "Hepatitis C virus entry: molecular biology and clinical implications." Hepatology 44(3): 527-35.
Kim, W. H. and F. Hong, et al. (2005). "Hepatitis B virus X protein sensitizes primary mouse hepatocytes to ethanol- and  TNF-alpha-induced apoptosis by a caspase-3-dependent mechanism." Cell Mol Immunol 2(1): 40-8.
Heller, T. and S. Saito, et al. (2005). "An in vitro model of hepatitis C virion production." Proc Natl Acad Sci U S A 102(7): 2579-83.
Baumert, T. F. and C. Yang, et al. (2005). "Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis  in primary Tupaia hepatocytes." Hepatology 41(2): 247-56.
Radaeva, S. and B. Jaruga, et al. (2004). "Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence  for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C." Biochem J 379(Pt 1): 199-208.
Liang, T. J. and T. Heller (2004). "Pathogenesis of hepatitis C-associated hepatocellular carcinoma." Gastroenterology 127(5 Suppl 1): S62-71.
Locarnini, S. and A. Hatzakis, et al. (2004). "Management of antiviral resistance in patients with chronic hepatitis B." Antivir Ther 9(5): 679-93.
Promrat, K. and D. H. McDermott, et al. (2003). "Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C." Gastroenterology 124(2): 352-60.
Milich, D. and T. J. Liang (2003). "Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection." Hepatology 38(5): 1075-86.
Soza, A. and J. E. Everhart, et al. (2002). "Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C." Hepatology 36(5): 1273-9.
Triyatni, M. and J. Vergalla, et al. (2002). "Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding." Virology 298(1): 124-32.
Mizukoshi, E. and M. Nascimbeni, et al. (2002). "Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies." J Virol 76(12): 6093-103.
Liang, T. J. and W. Zhang, et al. (2002). "[Clinical study on treatment of liver fibrosis in patients of hepatitis B by kangxian baogan decoction]." Zhongguo Zhong Xi Yi Jie He Za Zhi 22(5): 332-4.
Liang, T. J. and M. Ghany (2002). "Hepatitis B e Antigen--the dangerous endgame of hepatitis B." N Engl J Med 347(3): 208-10.
Zampino, R. and A. Marrone, et al. (2002). "Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment." J Viral Hepat 9(3): 183-8.
Zhang, Z. and N. Torii, et al. (2001). "X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and  induce protective immunity in vivo." J Clin Invest 108(10): 1523-31.
Thomson, M. and M. Nascimbeni, et al. (2001). "Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus." Gastroenterology 121(5): 1226-33.
Kim, W. H. and F. Hong, et al. (2001). "Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-independent and -dependent mechanisms." FASEB J 15(13): 2551-3.
Doo, E. and T. J. Liang (2001). "Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection." Gastroenterology 120(4): 1000-8.
Nemchinov, L. G. and T. J. Liang, et al. (2000). "Development of a plant-derived subunit vaccine candidate against hepatitis C virus." Arch Virol 145(12): 2557-73.
Lau, D. T. and M. F. Khokhar, et al. (2000). "Long-term therapy of chronic hepatitis B with lamivudine." Hepatology 32(4 Pt 1): 828-34.
Zhang, Z. and N. Torii, et al. (2000). "Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex." J Biol Chem 275(20): 15157-65.
Hu, Z. and Z. Zhang, et al. (1999). "Hepatitis B virus X protein is both a substrate and a potential inhibitor of the  proteasome complex." J Virol 73(9): 7231-40.
Baumert, T. F. and A. Marrone, et al. (1998). "Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression." J Virol 72(8): 6785-95.
Koziel, M. J. and T. J. Liang (1997). "DNA vaccines and viral hepatitis: are we going around in circles?" Gastroenterology 112(4): 1410-4.
Baumert, T. F. and S. A. Rogers, et al. (1996). "Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication." J Clin Invest 98(10): 2268-76.
Huang, J. and J. Kwong, et al. (1996). "Proteasome complex as a potential cellular target of hepatitis B virus X protein." J Virol 70(8): 5582-91.
Reid, A. E. and T. J. Liang (1995). "Association of hepatitis C virus and hepatocellular carcinoma in the United States." Princess Takamatsu Symp 25: 41-9.
Koziel, M. J. and T. J. Liang (1994). "Vaccination against hepatitis C virus infection: miles to go before we sleep." Hepatology 20(3): 758-60.
Hasegawa, K. and J. Huang, et al. (1994). "Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis." J Virol 68(3): 1651-9.
Liang, T. J. and H. J. Bodenheimer, et al. (1994). "Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification." J Med Virol 42(2): 151-7.
Liang, T. J. and K. Hasegawa, et al. (1994). "Hepatitis B virus precore mutation and fulminant hepatitis in the United States.  A polymerase chain reaction-based assay for the detection of specific mutation." J Clin Invest 93(2): 550-5.
Huang, J. and T. J. Liang (1993). "A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products." Mol Cell Biol 13(12): 7476-86.
Liang, T. J. and V. Rustgi, et al. (1993). "HCV RNA in patients with chronic hepatitis C treated with interferon-alpha." J Med Virol 40(1): 69-75.
Liang, T. J. and W. J. Makdisi, et al. (1993). "Targeted transfection and expression of hepatitis B viral DNA in human hepatoma cells." J Clin Invest 91(3): 1241-6.
Liang, T. J. and L. Jeffers, et al. (1993). "Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses." Gastroenterology 104(2): 556-62.
Wands, J. R. and T. J. Liang, et al. (1992). "Molecular pathogenesis of liver disease during persistent hepatitis B virus infection." Semin Liver Dis 12(3): 252-64.
Blum, H. E. and Z. S. Zhang, et al. (1992). "Hepatitis B virus X protein is not central to the viral life cycle in vitro." J Virol 66(2): 1223-7.
Liang, T. J. and K. Hasegawa, et al. (1991). "A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis." N Engl J Med 324(24): 1705-9.
Liang, T. J. and Y. Baruch, et al. (1991). "Hepatitis B virus infection in patients with idiopathic liver disease." Hepatology 13(6): 1044-51.
Blum, H. E. and E. Galun, et al. (1991). "Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication." J Virol 65(4): 1836-42.
Hasegawa, K. and J. K. Huang, et al. (1991). "Association of hepatitis B viral precore mutations with fulminant hepatitis B in  Japan." Virology 185(1): 460-3.
Blum, H. E. and T. J. Liang, et al. (1991). "Persistence of hepatitis B viral DNA after serological recovery from hepatitis B  virus infection." Hepatology 14(1): 56-63.
Liang, T. J. and H. E. Blum, et al. (1990). "Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers." Hepatology 12(2): 204-12.
Liang, T. J. and K. J. Isselbacher, et al. (1989). "Rapid identification of low level hepatitis B-related viral genome in serum." J Clin Invest 84(4): 1367-71.